SCHEMBL21539728

SCHEMBL21539728

COC(=O)C(F)(F)c1ccccc1OCc1ccnn1CC(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 2/20 0.36
RXRB P28702 2/20 0.36
RXRG P48443 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
MRGPRX4 Q96LA9 2/20 0.34
NOTUM Q6P988 1/20 0.34
PLCG1 P19174 1/20 0.33
MCL1 Q07820 3/20 0.33
UGCG Q16739 1/20 0.33
SGMS2 Q8NHU3 1/20 0.33
PDE10A Q9Y233 1/20 0.33
BTK Q06187 1/20 0.33
ATM Q13315 1/20 0.32
CACNA1G O43497 1/20 0.32
CACNA1H O95180 1/20 0.32
CACNA1I Q9P0X4 1/20 0.32
CYP2C8 P10632 1/20 0.32
NAMPT P43490 1/20 0.32
RBP4 P02753 2/20 0.32
TTR P02766 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21034207 0.83 RXRA (0.33) RXRARXRBRXRGL3MBTL1MRGPRX4
SCHEMBL21033756 0.83 RXRA (0.33) RXRARXRBRXRGL3MBTL1MRGPRX4
SCHEMBL21033755 0.83 RXRA (0.33) RXRARXRBRXRGL3MBTL1MRGPRX4
SCHEMBL21539820 0.81 RXRA (0.34) RXRARXRBRXRGMRGPRX4NOTUM
SCHEMBL21556805 0.80 L3MBTL1 (0.35) L3MBTL1UGCGPDE10ABTKATM
SCHEMBL21034307 0.80 RXRA (0.36) RXRARXRBRXRGMRGPRX4NOTUM
SCHEMBL21034301 0.80 NISCH (0.34) RXRARXRBRXRGMRGPRX4MCL1
SCHEMBL21034310 0.80 LMNA (0.44) L3MBTL1SGMS2
SCHEMBL21539729 0.80 L3MBTL1 (0.34) L3MBTL1UGCGPDE10ABTK
SCHEMBL21539746 0.79 SLC5A1 (0.33) RXRARXRBRXRGMRGPRX4MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10919908-B2 Thienopyrimidinone derivative and application thereof in preparing anticancer drug HENAN GENUINE BIOTECH CO., LTD. (CN) 2021-02-16 US disclosed
EP-3567043-A1 THIENOPYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MANUFACTURING OF ANTITUMOR DRUGS Henan Genuine Biotech Co., Ltd. (CN) 2019-11-13 EP disclosed
US-20190330230-A1 THIENOPYRIMIDINONE DERIVATIVE AND APPLICATION THEREOF IN PREPARING ANTICANCER DRUG HENAN GENUINE BIOTECH CO., LTD. (CN) 2019-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10919908-B2 Thienopyrimidinone derivative and application thereof in preparing anticancer drug CCND3, CCND1, CCND2 RXRA 3013/4885RXRB 2587/4885RXRG 3354/4885
US-20190330230-A1 THIENOPYRIMIDINONE DERIVATIVE AND APPLICATION THEREOF IN PREPARING ANTICANCER DRUG CCND3, CCND1, CCND2 RXRA 3013/4885RXRB 2587/4885RXRG 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.